Revance Therapeutics reported $17.37M in Gross Profit on Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Abbvie ABBV:US $ 9517M 1089M
Aerie Pharmaceuticals AERI:US $ 23.06M 85.54M
ALKERMES ALKS:US 223.39M 47.4M
Bristol Myers Squibb BMY:US $ 9177M 452M
Coherus Biosciences CHRS:US $ 50.74M 10.52M
Eli Lilly And LLY:US $ 5737.9M 211.8M
Endo International Ordinary Shares ENDP:US $ 472.5M 94.46M
Horizon Pharma HZNP:US $ 670.18M 102.77M
JAZZ PHA JAZZ:US $ 698.44M 62.14M
Johnson & Johnson JNJ:US $ 15828M 1021M
Merk MRK:US $ 10567M 873M
Neurocrine Biosciences NBIX:US $ 306M 1.9M
Pacira Pharmaceuticals PCRX:US $ 121.92M 1.73M
Procter & Gamble PG:US $ 9055M 1234M
Revance Therapeutics RVNC:US $ 17.37M 701K
Supernus Pharmaceuticals SUPN:US $ 134.57M 7.48M
Teva Pharmaceutical Industries TEVA:US $ 1802M 323M